• Categories:2020
• Author:
• Origin:
• Time of issue:2020-03-16
• Views:0

(Summary description)Biotheus recently announced to have reached strategic collaboration agreement with Finland’s TILT Biotherapeutics Ltd (TILT). According to the agreement, Biotheus will have the right to develop and commercialize of oncolytic virus TILT-123 authorized by TILT in the Greater China area (including Mainland China, Hong Kong, Taiwan and Macao).



TILT ® Technology is a new oncolytic virus developed based on sufficient research foundation of adenovirus which has unique characteristics and functions, and has comprehensive patent protection. TILT-123 is a human 5 / 3 chimeric adenovirus, which can only selectively replicate in most human tumor cells and play a role in oncolysis. In addition, the local expression of cytokines with immunomodulatory effect in tumor is expected to further improve the effect of anti-tumor therapy without increasing toxic effect and side effects.

Akseli Hemminki, MD, founder and CEO of TILT, said: "We are pleased to hand over our flagship product TILT-123 to Biotheus experts. TILT-123 is a unique product developed to activate T cells. At present, clinical development is about to be carried out in Europe and the United States. Biotheus team has rich experience in tumor immunotherapy and we believe that this cooperation will greatly support the global development and commercialization of TILT-123 and benefit cancer patients in China. "

Mr. Liu Xiaolin, founder and President of Biotheus, expressed: "We’re glad to cooperate with TILT and we thank TILT for its affirmation of our R& D ability. The introduction of TILT-123 project has well enriched our product pipeline in anti-tumor drugs. At present, the project is beginning the preparation of clinical application, and clinical trial application is expected to be submitted before the end of this year."

About TILT





Founded in 2013, TILT is a biopharmaceutical company specialized in the development of oncolytic adenovirus in Helsinki, Finland. Many oncolytic viruses developed by the company have been used in clinical trials as advanced therapeutic products. In 2019, the company announced that it had reached an agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the application value of its new generation oncolytic virus TILT-123 combined with anti-PD-L1 monoclonal antibody avelumab in routine treatment of refractory solid tumors. Tilt-123 is currently in phase I clinical trial in Denmark.